ATE228166T1 - Bifunktionelles protein, herstellung und verwendung - Google Patents

Bifunktionelles protein, herstellung und verwendung

Info

Publication number
ATE228166T1
ATE228166T1 AT95918576T AT95918576T ATE228166T1 AT E228166 T1 ATE228166 T1 AT E228166T1 AT 95918576 T AT95918576 T AT 95918576T AT 95918576 T AT95918576 T AT 95918576T AT E228166 T1 ATE228166 T1 AT E228166T1
Authority
AT
Austria
Prior art keywords
sub
hinge region
zeta
bifunctional protein
joined
Prior art date
Application number
AT95918576T
Other languages
English (en)
Inventor
Bernd Groner
Dirk Moritz
Original Assignee
Bernd Groner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernd Groner filed Critical Bernd Groner
Application granted granted Critical
Publication of ATE228166T1 publication Critical patent/ATE228166T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95918576T 1994-05-02 1995-04-20 Bifunktionelles protein, herstellung und verwendung ATE228166T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810244 1994-05-02
PCT/EP1995/001494 WO1995030014A1 (en) 1994-05-02 1995-04-20 Bifunctional protein, preparation and use

Publications (1)

Publication Number Publication Date
ATE228166T1 true ATE228166T1 (de) 2002-12-15

Family

ID=8218248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918576T ATE228166T1 (de) 1994-05-02 1995-04-20 Bifunktionelles protein, herstellung und verwendung

Country Status (18)

Country Link
US (1) US6984382B1 (de)
EP (1) EP0758394B1 (de)
JP (1) JP3742103B2 (de)
KR (1) KR100373813B1 (de)
AT (1) ATE228166T1 (de)
AU (1) AU694222B2 (de)
CA (1) CA2188422C (de)
DE (1) DE69528894T2 (de)
DK (1) DK0758394T3 (de)
ES (1) ES2185705T3 (de)
FI (1) FI119191B (de)
IL (1) IL113530A0 (de)
NO (1) NO316923B1 (de)
NZ (1) NZ285395A (de)
PT (1) PT758394E (de)
TW (1) TW428026B (de)
WO (1) WO1995030014A1 (de)
ZA (1) ZA953440B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69528894T2 (de) 1994-05-02 2003-03-27 Bernd Groner Bifunktionelles protein, herstellung und verwendung
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121113A1 (de) * 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
AU2005277831B2 (en) 2004-07-10 2012-11-22 The Institute For Cancer Research Genetically modified human natural killer cell lines
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008045437A2 (en) * 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP4282419A1 (de) 2012-12-20 2023-11-29 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087101B1 (de) 2013-12-20 2024-06-05 Novartis AG Regulierbarer chimärer antigenrezeptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
RU2021118125A (ru) 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP4643874A3 (de) 2015-12-22 2026-02-11 Novartis AG Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-inhibitor zur kombinierten verwendung in der antikrebstherapie
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
US20220221455A1 (en) * 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
EP4065157A1 (de) 2019-11-26 2022-10-05 Novartis AG Chimäre cd19- und cd22-antigen-rezeptoren und verwendungen davon
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE260880T1 (de) 1986-09-11 1988-11-03 Dana-Farber Cancer Institute, Inc., Boston, Mass. Verfahren zur ausloesung der zytotoxizitaet.
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
FI105320B (fi) 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1992010591A1 (en) * 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
AU1453792A (en) 1991-02-27 1992-10-06 Regents Of The University Of California, The Targeting complex mediated immunogenicity
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
EP0565794A1 (de) 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induktion von CTL-Antworten
DE69528894T2 (de) 1994-05-02 2003-03-27 Bernd Groner Bifunktionelles protein, herstellung und verwendung

Also Published As

Publication number Publication date
AU694222B2 (en) 1998-07-16
WO1995030014A1 (en) 1995-11-09
DE69528894T2 (de) 2003-03-27
FI964311L (fi) 1996-10-25
JP3742103B2 (ja) 2006-02-01
CA2188422C (en) 2011-03-15
NO964641D0 (no) 1996-11-01
NO964641L (no) 1996-11-01
US6984382B1 (en) 2006-01-10
DK0758394T3 (da) 2003-03-03
AU2446995A (en) 1995-11-29
PT758394E (pt) 2003-04-30
IL113530A0 (en) 1995-07-31
FI964311A0 (fi) 1996-10-25
JPH09512176A (ja) 1997-12-09
FI119191B (fi) 2008-08-29
CA2188422A1 (en) 1995-11-09
TW428026B (en) 2001-04-01
ZA953440B (en) 1995-11-02
NZ285395A (en) 1998-10-28
EP0758394A1 (de) 1997-02-19
EP0758394B1 (de) 2002-11-20
KR100373813B1 (ko) 2003-10-08
DE69528894D1 (de) 2003-01-02
ES2185705T3 (es) 2003-05-01
NO316923B1 (no) 2004-06-28

Similar Documents

Publication Publication Date Title
DE69528894D1 (de) Bifunktionelles protein, herstellung und verwendung
NO963018D0 (no) CTLA4-mutantmolekyler og anvendelser derav
NO934801D0 (no) CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav
WO2000023573A3 (en) Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
KR927003847A (ko) 수용체-결합된 신호 변환 경로를 위한 키메라 사슬
EP1878746A3 (de) Humane monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor
WO2002077029A3 (en) Cd19-specific redirected immune cells
IE890182L (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
GR3030415T3 (en) Platelet activating factor antagonists.
IL112390A0 (en) A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same
AU5762190A (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
AU5390194A (en) Methods for regulating the immune response using CTLA4-binding molecules and IL4-binding molecules
AU5215090A (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
HUT77253A (hu) CD4-csalireceptorokat és rokonszerkezetű molekulákat hordozó sejtek és alkalmazásuk
WO1996021028A3 (en) Soluble heterodimeric t cell receptors and their antibodies
AU5173996A (en) Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
DE69631624D1 (de) Antikörper gegen menschliches restrictin
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758394

Country of ref document: EP